Androgens and osteoporosis

Area of Science:

• Endocrinology
• Bone Biology
• Men's Health

Background:

• Osteoporosis in men is a significant public health issue.
• Recent advancements have clarified the mechanisms of androgen action on bone cells and in humans.
• Understanding androgens' role in bone loss pathophysiology can drive novel therapeutic strategies.

Purpose of the Study:

• To review the current understanding of androgen action in bone cells.
• To explore the role of androgens in male osteoporosis.
• To identify potential new treatments for bone loss.

Main Methods:

• Literature review of recent advances in androgen action and bone metabolism.
• Analysis of the direct and indirect effects of testosterone on bone cells.
• Evaluation of clinical data regarding testosterone therapy in men with osteoporosis.

Main Results:

• Androgen receptors are prevalent in bone cells, mediating testosterone's effects directly and indirectly via estrogen receptors.
• Androgen receptor activation positively influences periosteal growth and bone expansion, while ERalpha activation is inhibitory.
• Androgen deficiency is a key secondary cause of male osteoporosis, warranting testosterone treatment in symptomatic individuals.
• Testosterone is less effective as a first-line treatment for age-related bone loss compared to established therapies like bisphosphonates.

Conclusions:

• Testosterone therapy is indicated for men with symptomatic androgen deficiency and osteoporosis.
• Further randomized, placebo-controlled trials are necessary to assess testosterone's efficacy and safety in men with age-related testosterone decline and osteoporosis.
• These trials should rigorously evaluate fracture reduction and other health benefits of testosterone therapy.